AACR22: CAR T-cell/ mRNA vaccine for solid tumors – an interview with John Haanen

A study recently presented at the AACR 2022 Annual Meeting (8−13 April 2022; LA, USA) demonstrated that a CAR T-cell product in combination with an mRNA vaccine exhibits an acceptable safety profile and shows early signs of efficacy in patients with solid tumors. In this interview we speak with John Haanen (Netherlands Cancer Institute) to find out more about the preliminary data from this exciting Phase I/II trial. What are the next steps for the trial? The study will continue to find the recommended Phase II dose of CAR-T and based on further results a Phase II trial will start...